News coverage about Spectranetics (NASDAQ:SPNC) has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectranetics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 45.826314466897 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Spectranetics (SPNC) opened at $38.45 on Thursday. Spectranetics has a 12-month low of $19.80 and a 12-month high of $38.55. The company has a debt-to-equity ratio of 7.61, a current ratio of 1.92 and a quick ratio of 1.43.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Spectranetics (SPNC) Stock Price” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Insider Buying and Selling by Quarter for Spectranetics (NASDAQ:SPNC)

Receive News & Ratings for Spectranetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics and related companies with's FREE daily email newsletter.